Paul R. Kirchgraber - May 19, 2023 Form 4 Insider Report for LABORATORY CORP OF AMERICA HOLDINGS (LH)

Role
CEO, Covance Drug Development
Signature
/s/ Sandra van der Vaart, Attorney-in-Fact for Paul R. Kirchgraber
Stock symbol
LH
Transactions as of
May 19, 2023
Transactions value $
-$147,914
Form type
4
Date filed
5/23/2023, 08:06 AM
Previous filing
Apr 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LH Common Stock Options Exercise $785K +4.3K +33.21% $182.51 17.2K May 19, 2023 Direct
transaction LH Common Stock Sale -$933K -4.3K -24.93% $216.91 12.9K May 19, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LH Non-qualified Stock Options Options Exercise $0 -4.3K -100% $0.00* 0 May 19, 2023 Common Stock 4.3K $182.51 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.
F2 The option vested in three equal annual installments beginning on the date reflected in this column.